Lantern Pharma Inc. (LTRN): Price and Financial Metrics


Lantern Pharma Inc. (LTRN): $5.61

-0.29 (-4.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LTRN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LTRN Stock Price Chart Interactive Chart >

Price chart for LTRN

LTRN Price/Volume Stats

Current price $5.61 52-week high $16.50
Prev. close $5.90 52-week low $5.00
Day low $5.54 Volume 46,000
Day high $6.00 Avg. volume 39,538
50-day MA $6.45 Dividend yield N/A
200-day MA $8.38 Market Cap 60.76M

Lantern Pharma Inc. (LTRN) Company Bio


Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-11, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.


LTRN Latest News Stream


Event/Time News Detail
Loading, please wait...

LTRN Latest Social Stream


Loading social stream, please wait...

View Full LTRN Social Stream

Latest LTRN News From Around the Web

Below are the latest news stories about Lantern Pharma Inc that investors may wish to consider to help them evaluate LTRN as an investment opportunity.

Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio

Lantern Pharma (NASDAQ: LTRN), a Dallas-based clinical stage biopharmaceutical company using its proprietary artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it is expanding opportunities for its portfolio of drug candidates and A.I. drug discovery platform into additional rare pediatric cancers through a collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at the University

Yahoo | February 15, 2022

Analysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and Lantern Pharma (LTRN)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cocrystal Pharma (COCP – Research Report) and Lantern Pharma (LTRN – Research Report) with bullish sentiments. Cocrystal Pharma (COCP) In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Cocrystal Pharma, with a price target of $5.00. The company's shares closed last Monday at $0.55, close to its 52-week low of $0.47. According to TipRanks.

Brian Anderson on TipRanks | February 8, 2022

Sanders Morris Harris Llc Buys Roth CH Acquisition V Co, The Walt Disney Co, Mastercard Inc, ...

Investment company Sanders Morris Harris Llc (Current Portfolio) buys Roth CH Acquisition V Co, The Walt Disney Co, Mastercard Inc, Elanco Animal Health Inc, Hawks Acquisition Corp, sells Visa Inc, Endeavor Group Holdings Inc, Endeavor Group Holdings Inc, FedEx Corp, Splunk Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Sanders Morris Harris Llc.

Yahoo | February 2, 2022

RedChip Partners with Benzinga to Host Exclusive Small-Cap CEO Interview Series on January 28

ORLANDO, FL / ACCESSWIRE / January 26, 2022 / RedChip Companies, Inc., an international investor relations, media, and research firm focused on microcap and small-cap companies, is pleased to announce its partnership with Benzinga to host an exclusive series of CEO interviews on January 28, beginning at 9:15 a.

Yahoo | January 26, 2022

Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development today announced that the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation and Orphan Drug Designation for the company's drug candidate LP-184 for the treatment of pediatric patients with ATRT. LP-184 is being pursued as a potent

Yahoo | January 24, 2022

Read More 'LTRN' Stories Here

LTRN Price Returns

1-mo -5.87%
3-mo -8.93%
6-mo -33.53%
1-year -62.90%
3-year N/A
5-year N/A
YTD -29.70%
2021 -58.55%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6191 seconds.